Treatment_of_leiomyomata_uteri_with_leuprolide_acetate_depot:_a_double-blind,_placebo-controlled,_multicenter_study._The_Leuprolide_Study_Group._The_purpose_of_this_study_was_to_evaluate_efficacy_and_safety_parameters_in_women_with_leiomyomata_uteri_treated_with_the_GnRH_agonist_leuprolide_acetate_depot,_3.75_mg_intramuscularly_every_4_weeks_for_24_weeks._One_hundred_twenty-eight_patients_were_enrolled_in_a_randomized,_double-blind,_placebo-controlled_multicenter_study_involving_13_investigative_centers._Mean_uterine_volume_decreased_by_36%_at_12_weeks_and_45%_at_24_weeks_of_leuprolide_therapy._Patients_treated_with_placebo_had_increased_in_mean_uterine_volume_of_16%_at_12_weeks_and_5%_at_24_weeks._Seventy-seven_percent_of_leuprolide-treated_patients_had_a_more_than_25%_reduction_in_uterine_volume,_compared_with_9%_of_placebo-treated_controls._Mean_uterine_volume_returned_to_pre-treatment_size_24_weeks_after_cessation_of_leuprolide_treatment._The_majority_of_patients_had_resolution_or_improvement_of_their_fibroid-related_symptoms_after_24_weeks_of_leuprolide_treatment._Of_38_leuprolide-treated_patients_presenting_with_menorrhagia,_37_(97%)_had_resolution_of_this_symptom_at_the_time_of_the_final_visit._Although_95%_of_women_treated_with_leuprolide_acetate_experienced_some_side_effects_related_to_hypoestrogenism,_only_five_patients_(8%)_terminated_treatment_prematurely._We_conclude_that_leuprolide_acetate_depot_treatment_of_leiomyomata_uteri_is_safe_and_causes_significant_but_temporary_reductions_in_uterine_size_and_fibroid-related_symptoms.